A detailed history of Caption Management, LLC transactions in 89bio, Inc. stock. As of the latest transaction made, Caption Management, LLC holds 255,200 shares of ETNB stock, worth $2 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
255,200
Previous 474,900 46.26%
Holding current value
$2 Million
Previous $3.8 Million 50.35%
% of portfolio
0.03%
Previous 0.06%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$7.31 - $10.9 $834,918 - $1.24 Million
114,216 Added 81.01%
255,200 $2.04 Million
Q1 2024

May 15, 2024

SELL
$8.13 - $13.77 $967,600 - $1.64 Million
-119,016 Reduced 45.78%
140,984 $1.64 Million
Q4 2023

Feb 14, 2024

BUY
$6.66 - $16.03 $959,040 - $2.31 Million
144,000 Added 124.14%
260,000 $2.9 Million
Q3 2023

Nov 14, 2023

BUY
$15.06 - $19.41 $1.75 Million - $2.25 Million
116,000 New
116,000 $1.79 Million
Q1 2023

May 15, 2023

BUY
$10.48 - $16.94 $2.73 Million - $4.42 Million
260,638 New
260,638 $3.97 Million

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $365M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.